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Abstract 
 Paediatric high grade glioma (pHGG) represent a therapeutically challenging group of 
tumours. Despite decades of research there has been a minimal improvement in treatment and the 
clinical prognosis remains poor. Autophagy, a highly conserved process for recycling metabolic 
substrates is upregulated in pHGG, promoting tumour progression and evading cell death. There is 
significant cross talk between autophagy and a plethora of critical cellular pathways, many of which 
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are dysregulated in pHGG. The following article will discuss our current understanding of autophagy 
signalling in pHGG and the potential modulation of this network as a therapeutic target.  
 
Introduction 
Paediatric high grade glioma (pHGG) are aggressive and difficult to treat central nervous 
system tumours (1) and include grade III anaplastic astrocytoma, grade IV glioblastoma (GBM) and 
grade IV diffuse intrinsic pontine glioma (DIPG) (2). Despite significant research, a large number of 
clinical trials and improvements in pre- and intra-operative surgical imaging techniques, there has 
been little clinical improvement for these patients (3). The mean 2 year survival is between 10 and 
30% for pHGG patients, and is less than 1% for DIPG patients (4,5). There remains no standard 
treatment regimen for pHGG patients (6) and current therapy incorporates, where possible, gross 
maximal surgical resection, focal, fractionated radiotherapy, concomitant with, and followed by, 
aggressive combinatorial chemotherapy regimens (7–10).  
In patients under 5 years of age, radiotherapy may be spared or delayed to minimise 
irreversible neurocognitive sequalae which include neurological, endocrine function and cognitive 
impairment (11–13). Surgical resection is constrained within this patient population by tumour 
location which typically presents in proximity to functionally eloquent areas of the brain. Where 
surgery is not feasible, a biopsy may be taken for diagnostic and research purposes (14). The 
complete excision of the tumour is further complicated by the infiltrative nature of high grade 
neoplastic cells at the tumour border which invade into healthy brain parenchyma, a hallmark of 
pHGG. The cells that infiltrate into the surrounding non-neoplastic tissues typically undergo mitotic 
arrest and are highly resistant to conventional therapies that target rapidly dividing cells (15). 
Treatment is further complicated as the effective delivery of chemotherapeutics is impeded by the 
blood-brain barrier (BBB) which inhibits cytotoxic agents from permeating into the tumour. 
Furthermore, pHGGs are highly vascularised and demonstrate rapid and widespread remodelling of 
the vascular network to meet the metabolic demands of the tumour. Consequently, newly recruited 
blood vessels are disorganised and display increased fenestrations with weak, leaky vessel walls. 
These generate high interstitial pressure gradients, causing stagnated blood flow and excess fluid 
retention (16). Together, modulation of the vascular unit creates an extremely challenging clinical 
situation. The pHGG therapeutic has to cross the BBB, attain a therapeutically effective dose, and be 
retained at this concentration to mediate an effective clinical response.  While adult high grade 
glioma treatments have been developed, including the Stupp protocol where there is the 
incorporation of temozolomide (TMZ) with concomitant radiotherapy, these have not translated into 
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the paediatric population (7). The methylation of the O6-methylguanine-DNA-methyltransferase 
(MGMT) promoter predicts a subset of adult patients that are likelier to respond to TMZ treatment 
(17). In pHGG, MGMT promoter methylation, occurs in ~40% of patients, similar to that observed in 
aHGG. However, irrespective of MGMT promoter methylation status, TMZ treatment regimens have 
minimal benefit in pHGG patients. These data suggest an alternate, but as yet, poorly understood 
resistance mechanism in paediatric patients (18). Within the last decade our understanding of pHGG 
pathobiology has significantly increased. The identification of unique epigenetic and genetic driver 
mutations define specific patient subgroups. These correlate with tumour location, patient age and 
ultimately prognosis. Together, the molecular profiles of these tumours provide further compelling 
evidence for pHGG to be considered distinct diseases from their adult counterparts (4,19–21).  
Recent molecular meta-analysis has described distinct molecular subgroups in pHGG and 
DIPG tumours (22). The discovery of histone H3.3 (H3F3A) and H3.1 (HIST1H3B) K27M and G34R/V 
mutations that occur almost exclusively in paediatric tumours, has been a major step forward in the 
reclassification of these diseases. In light of this, the World Health Organisation (WHO) updated 
brain tumour classifications to reflect the novel group ‘diffuse midline glioma with H3K27M 
mutation’ to create more clinically relevant subtypes (22). Within histone mutant subtypes, further 
segregation occurred according to additional somatic co-mutations. Histone H3.3 G34R/V, restricted 
to the cerebral hemisphere, occurred with co-mutations of TP53, ATRX and F-box/WD repeat-
containing protein 7 (FBXW7). FBXW7 has been shown to promote MYC/MYCN signalling while the 
H3.3 G34R/V mutants were the only subgroup to harbour MGMT promoter methylation (22). H3.3 
K27M mutant tumours were present in over 60% of midline pHGG and DPIG tumours, and this 
mutation correlated with worse clinical prognosis. Co-mutations in PDGFR and FGFR1, were also 
noted in the H3.3 K27M tumours (4). These were alongside mutations in TOP3A, TP53, PPM1D and 
CCND2. In contrast, H3.1 K27M mutant tumours were exclusively restricted to the pons and 
correlated with significantly improved clinical prognosis. Co-mutations in the PI3K signalling pathway 
and activin A receptor, type I (ACVR1) were also common within this sub-group. 
These data are compelling and a thorough understanding of tumour pathobiology, including 
specificity in histone mutation and co-mutation expression may be key to defining clinically 
actionable sub-groups (22). However, care must be taken not to over-segregate tumour types into 
smaller and smaller patient cohorts as statistically relevant numbers for clinical trial enrolment may 
be difficult to achieve. Tumour reliance on common pathways including autophagy may prove a 
route to therapeutic intervention. This could be targeted alongside specific therapeutics according to 
specific intragroup co-mutations. The heterogeneity of pHGG tumours has resulted in many failed 
Phase II and III clinical trials using various small molecule inhibitors (4). Therapeutically targeting 
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common pathways, including autophagy across multiple tumour subgroups, in combination with 
subgroup or mutation specific therapeutics has attracted significant interest. This has driven a shift 
in focus to broader scale combinatorial approaches that target survival pathways in an attempt to 
sensitise pHGG cells to therapeutic intervention, potentially improving efficacy by circumventing 
resistance and off target effects (19,23).  
 
Autophagy. 
Autophagy is a catabolic process in which cellular components are degraded and recycled. 
Autophagy is regulated by, and in turn regulates, multiple signalling pathways, many of which are 
deregulated in pHGG and targetable with various inhibitors. It is hypothesised that a combinatorial 
therapeutic approach targeting essential pHGG survival pathways in addition to autophagy could 
overcome resistance mechanisms and provide an effective treatment of pHGG (24–27). Within this 
review we also include some of our own data which indicates targeting autophagy as an attractive 
therapy modality for pHGG. 
Autophagy is a homeostatic process by which cellular components are cycled to make 
available essential substrates (28). Cellular components for degradation are tagged and sequestered 
into double membraned vesicles. Fusion of these double membraned vesicles with a lysosome leads 
to the complete degradation of the contents, which are released into the cytoplasm (29). Autophagy 
occurs at a basal level in all cells, acting as a means to generate essential substrates or release 
sequestered molecules from long term stores (30). In response to stress or insult, including the 
action of chemo- and radio-therapy, autophagy is upregulated to provide essential substrates for 
growth and continued cell proliferation. First described in yeast, over 30 mammalian autophagy 
gene (ATG) homologues have been identified. The term ‘autophagy’ covers a range of mechanisms. 
These may act at a broad level termed macro-autophagy, or in a highly specific, orchestrated 
manner referred to as micro-autophagy. Autophagy can denote to the targeting of specific 
organelles, or occur in the absence of membrane vesicles (termed chaperone-mediated autophagy, 
CMA) (30) (31). An overview of these processes are shown in Figure 1. 
Microautophagy is at present poorly characterised, and the major proteins involved are as yet 
undefined in mammalian systems. Micro-autophagy is selective and is initiated by direct invagination 
of the endosomal or lysosomal membrane. Deformation and invagination of the membrane forms 
the autophagic tube, extending into the vacuole and encapsulating cytoplasmic contents. Extension 
of the autophagic tube occurs as transmembrane proteins are removed, resulting in lipid enrichment 
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of the membrane. The proximal end of the tube expands to form the autophagic body which 
eventually fuses, engulfing the cytoplasmic contents.   The fused autophagic body is untethered by 
scission and along with the contents, are degraded by hydrolases (32).  
Chaperone-mediated autophagy (CMA) plays an important role in transcriptional regulation, 
targeting transcription factors and associated inhibitors for degradation. CMA is upregulated in 
response to nutrient deprivation, toxic and oxidative stress. Selective protein recognition relies on 
presentation by the target protein of a KFERQ-motif, present in around 30% of cytosolic proteins. 
This recognition motif is usually inaccessible due to the 3D structure of protein: protein complexes. 
The KFERQ-motif becomes accessible via protein misfolding, partial protein unfolding or protein: 
protein dissociation (33). Presentation of the KFERQ-motif by individual proteins initiates the binding 
of heat shock protein 70 (hsp70) and additional co-chaperone proteins. The subsequent 
hsp70/substrate complex localises to the lysosomal membrane. This binding is mediated by 
Lysosomal Associated Membrane Protein-2A (LAMP-2A) and the lysosmal-heat shock protein 90 
complex. Once bound, the target protein is unfolded and translocated into the lysosomal lumen 
where it is degraded (34). In this way, recognition motif presentation by target proteins and the 
highly orchestrated cycling of LAMP-2A levels tightly regulate CMA (35).  
Mitophagy, or selective autophagy, is highly specific, targeting damaged or dysfunctional 
mitochondria. Mitophagy is regulated by PINK1 (PTEN-induced putative kinase) and Parkin (Parkin 
RBR E3 Ubiquitin Protein Ligase) which recognise dysfunctional mitochondria and initiate their 
autophagic engulfment. In healthy mitochondria, PINK1 binds to the mitochondrial membrane and is 
rapidly imported into the inner mitochondrial membrane where it is cleaved and afterward 
degraded by proteolysis. This rapid turn-over maintains a dynamic, but low cellular pool of PINK1. 
Following mitochondrial damage, the import and cleavage of PINK1 is inhibited (36). Unprocessed 
PINK1 rapidly accumulates on the surface of depolarised mitochondrial membranes. In the 
unprocessed state, PINK1 recruits cytosolic Parkin, an ubiquitin ligase. The exact mechanism by 
which this occurs is currently unknown. The binding of PINK1 and Parkin immobilises damaged 
mitochondria and prevents their interaction within the mitochondrial network. Parkin also mediates 
hyper-ubiquitination of the mitochondrial membrane, which is subsequently recognised by the 
ubiquitin-interacting autophagy proteins p62 and Lys63. At this stage the mitophagy and autophagy 
processes merge, where the machinery driving downstream engulfment and degradation are shared 
(36). At present, the exact mechanisms of mitophagy induction and its regulation are only just being 
uncovered. 
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Macroautophagy is an essential, conserved self-eating process that cells perform to allow the 
degradation of intracellular components which include soluble proteins, aggregated proteins, 
organelles, macromolecular complexes, pathogens. The dysregulation of macroautophagy has been 
implicated in many diseases including cancer. For this review, the term ‘autophagy’ refers to 
macroautophagy (37). Autophagy regulates many different biological processes during development, 
normal physiology, and in response to a wide variety of stresses.  
Autophagy and the associated networks that interplay with this process (summarized in Figure 
2) is controlled by growth factors and energy-sensing proteins, including the master autophagy 
regulator, the mammalian target of rapamycin (mTOR). The mTOR protein inhibits autophagy 
signalling when adequate nutrients are present. The adenosine monophosphate-activated protein 
kinase (AMPK) is an important regulator of mTOR (38). AMPK is activated by a decreasing ATP to 
AMP ratio and responds to this ratio change by reducing ATP-dependent processes within the cell. 
This leads to the phosphorylation and activation of Tuberous sclerosis proteins 1 and 2 (TSC1/TSC2) 
and inhibits the formation of the mTOR complex (Figure 2, network shown in green). This inhibition 
allows the formation of the ULK1 protein complex, itself directly activated by AMPK and the 
subsequent initiation of autophagy (Figure 2 shown in red). AMPK may also directly interact with and 
inhibit mTOR complex 1 (mTORC1), via phosphorylation of the Raptor subunit, inducing autophagy 
(39). Activation of the AMPK signalling pathway leads to phosphorylation and stabilisation of cyclin-
dependant kinase inhibitor p27, a key cell cycle inhibitor, stimulating autophagy in an attempt to 
provide sufficient substrates for cell cycle progression (40). Hypoxia, generated when the cellular 
oxygen demand is higher than oxygen availability stimulates autophagy signalling by activating 
Beclin1 and AMPK, inhibiting mTORC1. This promotes autophagy signalling via BNIP3 (Bcl2 
interacting protein-3) and ATG5 (Figure 2). Interestingly, hypoxia-induced autophagy is independent 
of hypoxia inducible factor (HIF), commonly elevated and observed in pHGG (41). Elevated cytokine 
signalling leads to the activation of AMPK-ULK1 and inhibition of mTORC1, inducing autophagy. 
Conversely, cytokines have also been shown to impair lysosomal function, blocking autophagic flux 
(42). Interestingly, cytosolic Ca2+ has been shown to trigger autophagy by interaction with AMPK, the 
c-Jun N-terminal kinase (JNK) and mTORC (Figure 2, shown in grey). Conversely, low levels of 
intracellular Ca2+, partially mediated by Ca2+ sequestration into the mitochondria has been shown to 
inhibit autophagy (Figure 2, shown in purple) (43).   
Under nutrient rich conditions, mTORC1 associates with the ULK1 and ULK2 protein 
complexes. The UNC-51-like kinase-1-FIP200 (FAK family kinase-interacting protein of 200kDa)-
ATG12-ATG101 complex phosphorylates ULK1, ULK2 and ATG13. Where nutrients are depleted, 
mTORC1 dissociates from the ULK1/2-ATG13 complex and mTORC1 activity is repressed. ULK1 and 
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ULK2 phosphorylate both FIP200 and ATG13 and the entire complex translocates to the phagophore 
assembly site. Under these conditions Beclin-1 is activated by ULK1 and ULK2, leading to the 
formation of the Beclin-1/hVPS34 (human vacuolar sorting protein-34)/p150 complex. This complex 
is required for protein recruitment to drive phagophore initiation and early autophagosome 
membrane synthesis. The transmembrane proteins ATG9 and vacuole membrane protein (VMP1) 
recruit lipids to the phagophore assembly site mediating autophagosome membrane elongation. 
Cellular components for degradation are tagged with Lys63 cargo recognition protein and 
sequestered into the double membrane phagophore during continued autophagosome membrane 
elongation. The maturation of the autophagosome relies on two ubiquitin-like (UBL) conjugation 
systems which partially overlap. These are ATG12 and light chain 3 (LC3). ATG12 UBL conjugation is 
initiated by the covalent binding of ATG12 to ATG5, catalysed by ATG7 and ATG10. The ATG12-ATG5 
complex binds to ATG16, forming the ATG12-ATG5-ATG16 protein complex which interacts with the 
LC3 UBL system. The ATG4 protease cleaves LC3, followed by the covalent binding of LC3 to 
phosphatidylethanolamine (PE), a cleavage event required for membrane elongation, cargo 
recognition, cargo sequestration, and autophagosome maturation. The mature autophagosome 
fuses with a lysosome and following this fusion, the autophagosome and contents are degraded and 
then released back into the cytoplasm (28,44). Lipidated LC3 (LC3-II) remains bound to the inner 
membrane of the autophagosome throughout the maturation and degradation processes, providing 
a useful marker for monitoring autophagy (45,46).  
Chemotherapeutic insult may induce autophagy independent of ATG5, ATG7 and LC3-II. In 
addition, autophagy induction due to glucose restriction may occur independent of ULK1 (47). Key to 
ULK1 independent autophagy is that mTOR activity no longer needs to be suppressed. Critically, both 
ULK-dependent and ULK-independent autophagy involve the common autophagic programme that 
includes LC3 processing and ATG5 function. 
Autophagy is a tightly regulated process, acting at different times as both a pro-survival or 
cell death pathway (30). Autophagic cell death is termed Type II cell death and typically acts 
independently of apoptosis (programmed, or type I cell death). Autophagy and apoptosis 
demonstrate a degree of exclusivity although through common upstream signalling proteins, can 
cross regulate each other (48). One of the main routes where autophagy can reduce the propensity 
to induce apoptosis is by mitophagy (36). Mitochondria are the cellular epicentres where pro-
survival and pro-death signals merge and cell fate following diverse cellular stresses (including 
chemotherapy assault) is decided. Consequently, damaged mitochondria are primed to instigate 
apoptosis and their removal by autophagy can increase the strength of the signal required to induce 
apoptosis (36). Similarly, autophagy can reduce the amount of pro-apoptotic proteins within the 
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cytoplasm, particularly of potent inducers such as Bax and caspase 8 (49,50). Conversely, autophagy 
can promote apoptosis by the depletion of endogenous inhibitors of apoptosis, a response observed 
in a number of genetic model organisms where developmental apoptotic events are abolished 
following the loss of critical ATGs (51,52). In addition, ATG7 elevates apoptosis following 
photodamage, directing lysosomal membrane permeabilisation that leads to apoptosis (53,54). The 
relationship between apoptosis and autophagy is highly context dependent and the subject of 
widespread debate. However, similar to apoptosis, the dysregulation of autophagy has been 
identified in a number of diseases, including inflammatory and neurodegenerative diseases and, of 
particular interest for this review article, cancer (55).   
Advances in genomic profiling and multi-centre collaborative projects, notably The Cancer 
Genome Atlas (TCGA) (56–58) have identified epigenetic and genetic mutations in pHGGs, 
harbouring aberrations in core signalling pathways that include p53 (26), RAS/RAF/MEK/Erk (59), 
PI3K/AKT/mTOR (60,61) and RTK/Ras/PI3K (4,56) (Figure 2). Frequently mutated in pHGG, these 
pathways regulate, or are regulated by autophagy. Consequently, these are highly promising 
therapeutic targets.  
 
The PI3K/AKT/mTOR Signalling Network. 
The phosphoinositide-3-kinase (PI3K) signalling network is extensive and regulates a 
plethora of cellular processes including proliferation, cell survival and metabolism (62) (Figure 2 
shown in green). PI3K signalling is one of the most frequently mutated pathways in all cancers 
(63,64). The PI3K family of lipid kinases activate signalling cascades that are mediated by diverse 
signalling effectors, including G-protein coupled receptors (GPCR), receptor tyrosine kinases (RTK) 
and cytokines (65).  Dysregulation of this network is a hallmark of cancer, particularly pHGG, driving 
and maintaining an oncogenic phenotype that includes uncontrolled cell growth and division, 
widespread metabolic alterations, genomic instability and chemotherapy resistance (66). A further 
group of PI3K related serine/threonine protein kinases (phosphatidylinositol-3-kinase related PIKKs) 
include ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), DNA-
dependent protein kinase (DNA-PK) and the autophagy master regulator mTOR. Each of these are 
capable of regulating autophagy in response to DNA damage (67). In canonical PI3K signalling, 
following ligand binding and activation of a membrane bound receptor, class I PI3K’s phosphorylate 
phosphatidylinositol-4,5-bisphosphate (PIP2), forming phosphatidylinositol-3,4, 5-bisphosphate (PIP3) 
(68). PIP3 recruits AKT and PDK1 to the plasma membrane by direct binding. PDK1 phosphorylates 
the activation loop of AKT, allowing AKT to regulate downstream pathways including the p53 
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network, protein synthesis and autophagy (69). PI3K signalling via PIP3 is negatively regulated by the 
phosphotensin homolog (PTEN), via dephosphorylation of PIP3 to PIP2 (70). PI3K signal activation is 
associated with poor patient prognosis and is common to both adult and paediatric HGG. However, 
the mechanisms of PI3K signal activation differ significantly between the adult and paediatric disease 
(71).  In adult high grade glioma, inactivating PTEN mutations are commonly observed. However, in 
pHGG patients, PTEN mutations are rarer and more commonly display loss of heterozygosity. 
Furthermore, the inhibition of PTEN following PTEN promoter methylation has been reported (22). 
Overall, the PI3K signalling pathway has been implicated in a high proportion of pHGG tumours and 
the PI3K network remains an attractive therapeutic target, in particular mTOR inhibitors. 
 
Regulation of the PI3K/AKT/mTOR network by PTEN. 
As mentioned above, PTEN is an important tumour suppressor and is frequently mutated in 
cancer (70). PTEN negatively regulates the PI3K/AKT/mTOR signalling cascade by dephosphorylating 
PIP3 to PIP2 (Figure 2). This dephosphorylation prevents the recruitment of AKT to the plasma 
membrane and inhibits downstream  signalling (72). Deactivation mutations within PTEN lead to the 
sustained signalling of the PI3K/AKT/mTOR pathway (70,73) via constitutive AKT activation. These 
mutations are less frequent in pHGG (5-15% of cases) than in aHGG with loss of heterozygosity (LOH) 
observed in <30% of cases (19,74,75).   However, PTEN promoter methylation, leading to decreased 
PTEN protein expression has been reported for pHGG (76). In addition, the allelic loss of PTEN in 
DIPG patients has been described (77). These provide a potential mechanism for the 
PI3K/AKT/mTOR pathway activation observed in pHGG.  Activation mutations within the PIK3CA 
catalytic subunit or the PIK3R1 regulatory subunit are observed in approximately 20% of all pHGG, a 
similar frequency to the percentage observed in the adult HGG population (19,78).  Such activation 
mutations could lead to an increase in autophagy through the inhibition of AKT phosphorylation, 
blocking mTOR and downstream signalling and allowing the transcription of autophagy related genes 
mediated by the fork-head transcription factor FOXO3a.  
 
Autophagy regulation via mTOR. 
The key regulator of autophagy mTOR, exists in one of two complexes that control multiple 
cellular processes (66). mTORC1 primarily regulates proliferation, protein synthesis and autophagy 
via growth factor signalling and nutrient and energy sensing. In contrast, mTORC2 primarily regulates 
metabolism and survival signalling. The formation of mTORC1 or 2 is determined by the upstream 
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regulatory activators. These are the regulatory-associated protein of mTOR (RAPTOR) and the 
rapamycin-insensitive companion of mTOR (RICTOR) (47,79). The depletion of mTORC2 and 
inhibition of AKT reduces the phosphorylation of the FOXO3a transcription factor allowing FOXO3a 
nuclear accumulation. This nuclear retention allows the FOXO3a-dependent transcription of 
numerous autophagy genes (80). It is important to note that mTORC2 regulation by the PI3K/AKT 
signalling is poorly understood in contrast to mTORC1, although the two may act competitively (81–
83). To date, mTORC2 is understood to be required for complete activation of AKT. AKT activation of 
mTORC1 may reduce the total available mTOR, consequently decreasing AKT phosphorylation and 
disrupting autophagy and cell survival signalling (69,84). Compensatory signalling via mTORC2 when 
mTORC1 is abrogated could provide an important resistance mechanism to multiple mTOR inhibitors 
which have been evaluated to date (69,85).  In addition, the PI3K/AKT/mTOR signalling network is 
auto-regulated by several negative feedback loops, the dysregulation of which may also lead to 
constitutive activation of mTOR signalling (86).  
Upstream of mTOR, AKT promotes mTOR signalling by phosphorylating tuberculosis sclerosis 
2 (TSC2) at multiple residues, preventing TSC1/TSC2 complex formation and disabling Ras homology 
enriched in brain (Rheb) inhibition (60) (Figure 2). This stimulates mTORC1 complex formation and 
drives downstream signalling.  The inactivation of TSC2 by AKT leads to an increase in mTORC2 
activity, although the mechanism(s) of mTORC2 regulation by TSC1/TSC2 still remains unclear (87).  
Post-translational modifications also have a direct role in autophagy regulation. Under 
nutrient rich conditions, G9A, a methyltransferase, associates with chromatin in the promoter region 
of ATGs. This prevents chromatin unwinding and transcription suppression. Following nutrient 
depletion, G9A dissociates from chromatin, permitting access to and transcription of the ATGs (88). 
This is supported by a proposed role for epigenetic regulation in the maintenance of the autophagy 
response. This is by the activation of AMPK and the subsequent downstream phosphorylation of 
FOXO3a, stabilising inducers of autophagy and lysosome components (89). 
 
The DNA Damage Response. 
The DNA Damage response (DDR) (Figure 2, shown in blue) primarily co-ordinates the 
recognition and repair of DNA lesions, in a highly orchestrated manner dependent on the nature of 
the damage and cell cycle phase at the time of DNA damage (90,91). Repair processes include direct 
DNA repair, a single step process to remove agents bound to and distorting DNA strand(s). Single 
strand break repair is mediated by base excision repair (BER), nucleotide excision repair (NER), and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
mismatch repair (MMR). The repair of complex double strand breaks is conducted by single strand 
annealing (SSA), non-homologous end joining (NHEJ) or homologous recombination (HR). Multiple 
chemotherapeutics, as well as radiotherapy, induce widespread DNA damage via DNA-helix 
distorting reactive molecules, or the induction of direct DNA strand breaks (92). If left unresolved, 
this DNA damage in tandem with multiple stalled replication forks, signals catastrophic damage 
where the cell directs the induction of cell death pathways (93,94).  Three PIKK protein kinases are 
involved in directing the DDR, sensing damage and directing the repair process. Ataxia-
Telangiesctasia mutated (ATM) and the DNA-dependent protein kinase (DNA-PK) respond to double 
strand breaks, while Ataxia telangiectasia and Rad3-related protein (ATR) is activated following 
single strand breaks.  Aberrations in the DDR, including the inhibition or evasion of cell death 
pathways, are a major source of genomic instability and therapeutic resistance in almost all cancers 
(95).  
There is complex interaction between the DDR, the tumour suppressor and “guardian of the 
genome” p53 and the process of autophagy (Figure 2). Following irradiation or chemotherapy, DNA 
damage is frequently observed in conjunction with autophagy, indicative of cross-talk between these 
networks (92). Following double strand DNA (dsDNA) breaks, ATM is activated, (via the MRN 
complex composed of Mre11, Nbs1 and Rad50), inhibiting mTORC1, mediated by AMPK. 
Downstream of ATM, TSC1/2 is activated driving the dephosphorylation of ATG13 and ULK1/2. 
Unphosphorylated ULK1/2 triggers the phosphorylation of both FIP200 and ATG13, leading to the 
formation and activation of the ULK1/2-ATG13-FIP200 complex. The protein complex translocates to 
the phagophore assembly site, initiating autophagy (96). In addition, ATM directly phosphorylates 
and stabilises p53, leading to the transcriptional regulation of autophagy by AMPK, itself forming a 
positive feedback loop with p53. Following ssDNA breaks, energy consuming PARP1 (Poly [ADP-
ribose] polymerase 1) activation depletes cellular NAD+ (β-nicotinamide adenine dinucleotide) and 
ATP, leading to significant energy depletion within the cell. This depletion activates AMPK and 
increases autophagy (97). The majority of dsDNA breaks are repaired by NHEJ, where sister 
chromatids are absent and unable to provide a repair template. Where DNA damage is catastrophic, 
DNA-PK mediates apoptosis via activation of p53, suppression of pro-survival signalling and 
induction of  pro-apoptotic gene expression (98–100). Autophagy is significantly induced upon 
irradiation and the knockdown of Beclin-1 leads to the disruption of Ku70 and Ku80 protein 
translocation from the nucleus, preventing recruitment of DNA-PKCS to dsDNA breaks and failure to 
mediate DNA repair (101).  Clinical studies have shown that DNA-PKCS over-expression correlates 
with glioma progression (102), poor clinical response and resistance to DNA damage inducing 
chemo- and radio-therapy regimens (103). DNA-PKCS inhibition increased cell death in glioblastoma 
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cells by the disruption of NHEJ and the sensitisation of exposed cells to telomerase inhibitors (104). 
Strikingly, the inhibition of DNA-PKCS sensitized glioma cells to irradiation by inhibiting autophagy, 
supporting the theory of autophagy-mediated irradiation resistance and the dependence of HGG 
cells on autophagy (105,106). 
Interestingly, autophagy is involved in the regulation and completion of the DDR by 
maintaining adequate pools of substrates required for DNA repair. An adequate supply of ATP is 
required for chromatin remodelling and relaxation of DNA, allowing DNA repair proteins to access 
lesions. During the DDR there is a cellular reduction of processes that have a high ATP demand, 
ensuring that the cell has sufficient energy reserves to enable DNA repair to occur. The level of NAD+ 
required for PARP1 function and maintenance of the cellular deoxyribonucleotide triphosphate pool 
for replication and repair is tightly regulated by autophagy. Where DNA damage is excessive or DNA 
repair is defective, fragmented chromosomes may be sequestered and degraded by 
autophagosomes. Upon DNA repair completion, autophagy regulates the sequestration and 
degradation of DNA damage response proteins, that are themselves substantial macromolecular 
complexes (107).  A decrease in autophagic flux has been associated with the accumulation of DNA 
damage, either by the sustained increase in reactive oxygen species (ROS), or by the inhibition of the 
DDR protein complexes (107,108). Considering the inherent genomic instability noted in pHGG and 
the drive for continuous cell division, modulating autophagy is of vital importance for the continued 
survival of pHGG cells. 
Cross talk between autophagy and the DDR also regulates additional cellular processes. In 
particular, cell cycle progression is regulated by ATM and ATR which following activation, 
phosphorylate Checkpoint kinase-1 and Checkpoint Kinase-2 (CHK1/CHK2) preventing cell cycle 
progression. There is also  transcriptional activation or repression of DDR genes via p53 and FOXO3a 
and, where repair cannot be completed effectively, initiation of programmed cell death via 
apoptosis, necrosis or autophagic cell death (109).  A more complete understanding of the role the 
DDR plays in inducing and regulating autophagy (and vice versa) may be key to increasing pHGG 
sensitivity to chemo- and radio-therapy regimens. This could be via either inhibition of autophagy to 
circumvent pro-survival signalling and promoting apoptosis, or the hyper-activating autophagy 
towards inhibition of DNA damage response and promoting autophagic cell death (autosis) (110).  
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Epigenetic regulation and impact on the DDR and autophagy in pHGG. 
Exome sequencing has revealed that somatic histone mutations occur at high frequency in 
pHGG. It has been reported that up to 80% of brain stem (including DIPG) and 20% of non-brain 
stem pHGG present with somatic histone mutations and the presence of these correlate with patient 
prognosis (111,112). The most frequent mutations are amino acid substitutions that lead to variants 
of core histones H1 and H3, at K27 (K27M) and less frequently, G34 (G34R/V) residues (Figure 2, 
shown in blue). Histone H3 plays an important role in replication, transcription and DNA repair, and 
frequently occurs in conjunction with TP53 mutations. It is reported that up to 83% of tumours with 
K27M mutations present TP53 co-mutations, 40% harbour Platelet derived growth factor receptor A 
(PDGFRA) co-mutation and 30% show co mutation in Activin A Receptor Type 1 (ACVR1) (111,113). 
These data underline the substantive genetic instability inherent within these tumours. 
DNA methylation plays a key role in gene expression, typically supressing transcription and 
mediating downstream signalling (89). A mechanism was proposed where histone deacetylases 
(HDACs) regulate chromosome stability via ATR and the DDR by the degradation of key proteins 
mediated by autophagy (114).  The dysregulation of autophagy and associated regulatory pathways 
play a critical role in telomere stability (regulated by DNA-PK) in pHGG, which in turn are 
epigenetically regulated. In DIPG, ATRX-DAXX (Alpha Thalassemia/Mental Retardation Syndrome X-
Linked / Death Domain Associated protein) mutations occur in ~9% of cases, but of these, 100% co-
occur with mutation of HIST1H3B. The H3.3-ATRX-DAXX complex plays an essential role in chromatin 
remodelling and subsequently in telomere maintenance and stability. The depletion of components 
within this protein complex leads to the destabilisation of telomeres and an increase in alternate 
lengthening of telomeres (ALT). These contribute to the substantial genomic instability and therapy 
resistance in these paediatric tumours (115). Together, these data describe the significant cross talk 
between DNA damage signalling, DDR and autophagy regulation in pHGG. 
 
Growth factor signalling and autophagy in pHGG. 
Growth factor signalling regulates multiple essential cellular processes including 
proliferation, differentiation and angiogenesis. Binding of growth factors to transmembrane 
receptors leads to downstream signalling and the regulation of gene expression. Vascular 
endothelial growth factor (VEGF) signalling is upregulated in pHGG, increasing vasculature and 
permeability to meet the elevated energetic demands of the growing tumour (116). Strikingly, pHGG 
are some of the most vascularised tumours studied and consequently, anti-angiogenic therapies 
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have generated much excitement. Bevacizumab, an anti-VEGF humanised monoclonal antibody 
therapy was viewed with great enthusiasm for the treatment of pHGG both as a single agent and as 
part of a combinatorial chemotherapeutic regimen. Bevacizumab acts to reduce tumour vasculature 
and increase vascular permeability by inhibiting VEGF.  However, Bevacizumab alone, or in 
combination with chemotherapy in paediatric patients has not shown significant efficacy (117), 
despite being well tolerated (118–120). It has been suggested that resistance may be mediated by 
HIF1α activated autophagy (121). As areas of the tumour become devascularised they become 
increasingly hypoxic and nutrient depleted. Within this microenvironment, autophagy is induced via 
HIF1α/AMPK to maintain energy and substrate availability for the neoplastic cells (122). Therefore, 
the hyper-activation or the inhibition of autophagy, in addition to anti-angiogenic therapies (e.g. 
clonidine, chloroquine or rapalogues) could potentially overcome this  autophagy mediated 
resistance, sensitizing pHGG to anti-VEGF therapeutics (122). Epidermal growth factor receptor 
(EGFR) mutations (including EGFRvIII) that lead to constitutive EGFR activation are one of the most 
frequent events in aHGG, but are rare in pHGG patients (71,74). However, within the paediatric 
population, rather than EGFR mutations, there are instead frequent gene amplifications and 
consequently, the substantial overexpression of EGFR. Elevated EGFR protein expression is a poor 
prognostic factor for overall survival in pHGG patients (123,124). Importantly, EGFR negatively 
regulates autophagy signalling by activating the PI3K/AKT/mTOR network, increasing RAS signalling, 
inhibiting of Beclin-1 and hyper-elevating intracellular glucose levels by the stabilisation of the 
sodium/glucose co-transporter SGLT1 (125,126). Similarly, Platelet derived growth factor receptor 
(PDGFR) and signalling is a major driver and regulator of the pHGG phenotype. PDGFR is involved in 
differentiation, motility and is a major regulator of angiogenesis. Consequently, PDGFR dysregulation 
(including focal and copy number amplifications) as well as PDGFR protein activation is a major 
driver and frequently observed  in pHGG (71,74,77,127). Sequencing of DIPG patient tissue samples 
revealed PDGR amplification/gain of function, correlating with the most clinically aggressive tumours 
and leading to the hypothesis that PDGFR mutation is an early oncogenic driver event in DIPG 
tumours (128). To date, there has been limited success in clinical trials utilising RTK inhibitors. 
Aberrations of the receptor tyrosine kinases EGFR, PDGFR and VEGF in pHGG, and the induction of 
autophagy following RTK inhibition (129), suggest a possible therapeutic role for autophagy 
modulation in combination with these agents as potential treatments for pHGG (130–132). 
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Autophagy protein expression in pHGG patients. 
While there have been attempts to either promote or suppress autophagy as a therapeutic 
target in a range of cancers, the expression of key autophagy proteins has not been examined in 
tissue arrays from pHGG patients. This raised the interesting question as to whether there was 
robust expression of critical autophagy proteins in these tumours and if there was protein 
expression, whether they could be therapeutically targeted. We obtained a range of tissue 
microarrays (TMA) from 20 pHGG patients prior to treatment. These biopsy samples incorporated a 
diverse range of tumour locations (Figure 3a). With the exception of one tumour within the 
cerebellum, all of the others were supratentorial. From our small panel, most tumours originated 
within either the temporal lobe or the frontal lobe. Within this small cohort, 41% of the primary 
tumours were classified by neuropathologists as grade IV glioblastoma multiforme (GBM) using pre-
2016 WHO groupings. 47% were histologically classified as grade III anaplastic astrocytoma while 
11% were classified as grade III anaplastic oligodendroglioma. All patients were incorporated into 
the CNS 9204 clinical trial (133). Overall patient survival of this cohort was 357 days (Figure 3B) 
where patient survival varied from 57 days post-diagnosis up to 2625 days post-diagnosis where 
patient #7 demonstrated a complete response following therapy (Figure 3c). Treatment naïve 
samples were stained for LC-3 A/B and Beclin-1 (Figure 3c). All stains were validated by a 
neuropathologist prior to quantification, and where protein scoring was quantified, a score of high 
positive, positive, low positive or negative was assigned for each patient core for each protein of 
interest (134). The autophagy marker Beclin-1 was selected for staining as this protein is essential for 
early autophagy induction and is a critical component of functional autophagosomes. The autophagy 
protein LC3 A/B is required for autophagosome membrane initiation and elongation (135) and is in 
general, considered the gold standard protein for the evaluation of autophagy. Strikingly, we note 
that there was significant, widespread positive staining for both Beclin-1 and LC3 A/B in many of 
these treatment naïve patient biopsies. These data raised the interesting hypothesis that pHGG 
tumours have a requirement on a basal level of autophagy to provide sufficient energy and 
metabolic precursors for their continued growth and division. These observations and hypotheses 
are supported by published data that glial tumours exploit low level autophagy for nutrient cycling, 
whereas healthy brain tissues do not (136,137). This proposed reliance on basal autophagy 
represents an important therapeutic vulnerability, and a possible route to sensitizing glioma cells to 
therapeutic interventions.  It is of particular interest that basal autophagy is present in a diverse 
number of pHGG tumours. It is known from extensive genomic studies in pHGG tumours that these 
samples would be highly heterogeneous. This suggests that the therapeutic modulation of 
autophagy may be applicable to treat a wide range of paediatric glioma patients across many 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
different sub-types. This is striking when one considers current approaches to examine the entire, 
highly heterogeneous genetic composition of pHGGs and from these studies, the further 
stratification and sub division of small patient populations. While this can identify unique tumour 
drivers  and form a personalised medicine treatment platform(s), there are concerns regarding 
patient number and that if an appropriate treatment target were identified, if this agent would even 
be developed by the pharmaceutical industry (138). The general, widespread staining of key 
autophagy proteins suggests that targeting these, in combination with other standard therapeutics 
could offer significant promise to pHGG patients by circumventing such genetic heterogeneity.  
We noted a striking observation in one particular patient TMA core sample set. First, in this 
patient, the HGG core was one of the few negative TMA cores for both Beclin-1 and LC3 A/B (Figure 
4). This patient was incorporated into the UKCCSG/SIOP CNS 9204 trial. Within this trial, the patient 
underwent an aggressive chemotherapeutic regimen of; course 1, day 0, vincristine (iv bolus) 1.5 
mg/m2, carboplatin (iv over 4 h) 550 mg/m2; course 2, day 14 vincristine (iv bolus) 1.5 mg/m2, 
methotrexate 8000 mg/m2, folinic acid mg fixed dose; course 3, day 28, vincristine (iv bolus) 1.5 
mg/m2, cyclophosphamide 1500 mg/m2, mesna 1800 mg/m2; course 4, day 42, cisplatinum 
continuous infusion for 48 h 40 mg/m2 (138). Following disease recurrence, the relapsed tumour was 
biopsied allowing us to stain this relapsed tumour for both Beclin-1 and LC3 A/B (Figure 4). 
Significantly, in the relapsed treated tumour TMA, Beclin-1 and LC3 A/B protein expression was 
positive and in many regions, highly positive. Critically, both the original biopsy core and relapse 
tumour cores were within the same TMA and stained together for each protein. These data are in 
line with current literature where radio- and chemo-therapy exposure (including cisplatin) has been 
shown to induce autophagy (15,139,140), mediated by the generation of ROS, endoplasmic 
reticulum stress, hypoxia, DNA damage and inflammatory signalling. These data suggest that an 
increase in autophagy presents an important mechanism of resistance and we propose this could be 
therapeutically targetable in pHGG. In addition to sensitizing therapeutics, abrogation or hyper-
activation of autophagy may help to minimise tumour regrowth and prevent malignant progression. 
Importantly, these data raised the hypothesis that agents that modulate autophagy could be of 
significant interest in the treatment and potential management of relapsed disease, where at 
present, there are highly limited therapeutic options. Considering the dire clinical prognosis 
following disease relapse, this is of compelling interest to the field.  
Autophagy has been proposed as a ‘cell-fate decision maker’. These decisions may direct 
tumour suppression or promotion although each are context and stimuli dependent. The tumour 
micro-environment and cellular context can also direct autophagy-dependent cell fate (141). The 
appropriate abrogation or promotion of autophagy may drive or rescue programmed cell death 
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mechanisms by reprogramming signalling networks and sensitizing tumours to chemo- and radio-
therapy (142–144). These are compelling in pHGG patients where chemo- or radio-therapy 
sensitisation could have a profound impact on patient prognosis. 
 
Autophagy-mediated chemo- and radiotherapy resistance. 
 As considered above, autophagy has been shown to contribute to chemo- and radio-therapy 
resistance. Indeed, the protein expression differences in essential autophagy proteins between 
treatment naïve biopsy samples and relapse biopsy samples following an aggressive multi-drug 
treatment regimen is compelling, albeit from limited patient numbers (Figure 4). These types of 
therapy have been shown to induce cryoprotective autophagy by promoting the transcription of 
autophagy genes including Beclin-1 and various ATGs, as well as inducing the sustained inhibition of 
AKT/mTOR and AMPK (145). Furthermore, non-DNA targeting chemotherapies used to treat pHGG 
may stimulate autophagy by increasing ROS production and hypoxia inducing chemotherapies for 
pHGG patients may stimulate AMPK and HIF-1α activation, impacting autophagy, driving resistance.   
The RAS/RAF/MEK/Erk signalling pathway relays signals from the extracellular environment 
to the nucleus, and is involved in cell proliferation, differentiation and survival (146). The BRAFV600E 
mutation results in a truncated BRAF protein, allowing monomeric BRAF to activate signalling, rather 
than requiring dimer formation. This mutation increases signalling through the MAPK/Erk signalling 
cascade, driving tumour growth. BRAFV600E has been reported in approximately 20% of all pHGG 
compared to <10% in pLGG and approximately 5% in aHGG (147). BRAFV600E mutant cells show 
elevated autophagy and are resistant to multiple therapeutic interventions, including to the BRAF 
inhibitor Vemurafenib (148). However, following autophagy inhibition, these tumours are sensitized 
to RAF or PI3K inhibitors (149).  
 
Clinical application of autophagy modulation in pHGG. 
A major focus for targeting autophagy has been inhibition of mTOR with rapamycin or 
rapalogs including sirolimus, evirolimus and temsirolimus. These approaches and trials are 
summarized in table 1. Rapamycin and rapalogs have high specificity for mTORC1 where they bind to 
and induce a conformational change in the mTORC1 catalytic ATP-binding site. This change prevents 
the  phosphorylation of mTOR and ablates downstream signalling (150).  Phase I trials with 
rapamycin (sirolimus), in combination with additional chemotherapeutics were well tolerated in 
pHGG patients, but demonstrated minimal anti-tumour efficacy (151). Additional clinical trials with 
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rapalogs are in progress and include sirolimus alone (NCT01331135), rapamycin and HIF1α inhibitor 
Irinotecan (NCT01282697), and the oral administration of sirolimus, cyclophosphamide and 
topotecan (NCT01670175). Three clinical trials including Evirolimus are currently in progress for 
paediatric patients, including a feasibility study for treatment based on tumour biopsy 
(NCT02015728), non-randomized phase I trials for refractory and recurrent brain tumours 
(NCT00187174, NCT03387020) and  NCT02233049, a randomised phase II trial recruiting DIPG 
patients where treatment regimens are directed against EGFR overexpression, PTEN loss or 
combination mutations. Temsirolimus (a rapalog) has been well tolerated in phase I (152) and phase 
II (153) clinical trials,  where disease stabilisation was reported in the phase II trial. However, there 
was no significant treatment efficacy and the trial was halted. A phase I trial (NCT01614795) of 
combined temsirolimus and cixutumumab also reported good patient tolerance, although a limited 
treatment response in recurrent brain tumours was noted (154). A further phase I trial 
(NCT00880282) has been completed recently with results expected soon. A MATCH trial with 
mTOR/DNA-PK dual inhibitor is currently recruiting (NCT03213678). Taken together these results 
should be viewed positively, with temsirolimus being well tolerated over long term use, and could 
therefore be a promising candidate for future combinatorial approaches. The limited anti-tumour 
effect of rapamycin and rapalogs may be explained by their specificity for mTORC1, and not 
mTORC2, permitting compensatory resistance signalling. This may be by the hyper-activation of AKT 
via mTORC1 inactivation and positive feedback signalling though uninhibited mTORC2.  Additionally, 
aberrant p53 signalling and PTEN co-deletion events may lead to constitutively activated mTORC2 
signalling (80), increasing acetylation of FOXO3a, stimulating c-Myc signalling and mediating 
glycolysis (80). Only recently discovered, mTORC2 signalling is highly complex and plays an important 
role in chemotherapeutic resistance (155). There is great interest in developing efficient, specific, 
dual targeting inhibitors of mTORC1 and mTORC2, including second generation ATP-competitive 
mTOR inhibitors.  The dual mTORC1 and mTORC2 inhibitor, AZD2014, with combined 
chemotherapeutics, is currently in proof of concept studies for relapsed and refractory tumours 
(NCT02813135), although to date, their clinical efficacy remains to be proven.  
Activation of the PI3K signalling network, by targeting multiple effector and activator 
signalling nodes, is an attractive therapeutic target. There has been significant research efforts 
invested in characterising and progressing PI3K inhibitors into clinical trials (156). Over 30 agents 
covering PI3K  Class 1 pan specific inhibitors (including Pictilisib, Buparlisib, Pilaralisib) and PI3K 
isoform-specific inhibitors (including Idelalisib) have entered pHGG clinical trials (68,86).  
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Recent data from Levy et al show in vitro and ex vivo evidence that inhibition of autophagy 
in BRAFV600 mutant brain tumours overcomes multiple mechanisms of resistance to kinase 
inhibitors. Although the sample size is small, and proof of concept studies are yet to be carried out in 
vivo, this is positive evidence of the role autophagy plays in mediating chemotherapy resistance (24).  
Additional clinical trials targeting BRAFV600E mutations include Phase I clinical trials with Dabrafenib 
(NCT01677741) and Vemurafenib (NCT01748149), and an additional Phase II trial with Dabrafenib  
and the MEK 1/2 inhibitor Trametinib (NCT02684058) continue to recruit patients. Phase I and Phase 
II trials targeting RTK inhibitors include combined Bevacizumab with Lapatinib (NCT00883688); GDC-
0084 for DIPG and midline glioma (NCT03696355); PCT299, a VEGF inhibitor (NCT01158300) and 
Erlotinib in combination with temozolomide (NCT00077454). A Phase 1 trial targeting MDMx/MDM2 
inhibition, rescuing wild-type p53 stabilisation with ALRN-6924, (NCT03654716) has also been 
initiated.  
It is less complicated to inhibit activation signalling than it is to recover loss-of-function in 
diverse, complex signalling networks. Despite this significant research investment, there has been 
only a modest return, with resistance and toxicity continuing to be the mainstay of trial failure (157).  
Frequently, targeted inhibitors are cytostatic rather than cytotoxic, both in vitro and in vivo. A 
combinatorial treatment approach, combining upstream inhibitors with chemotherapeutics 
targeting additional signalling nodes, may provide a mechanism of complete pathway abrogation 
and more effective pHGG treatment regimes. 
 
Concluding remarks. 
Autophagy is a complex process and there is significant cross talk between networks that 
regulate, or are regulated by, autophagy signalling. These include the PI3K, p53 and DDR. Autophagy 
should also be considered both a transient and dynamic process where the timing of the application 
of therapeutic intervention(s) requires careful consideration. The exact role autophagy plays in 
pHGG survival, proliferation and therapeutic resistance continues to be widely debated. The 
pathway is intricate, with multiple regulatory and inhibitory factors, mediating multiple pro- and 
anti- cell death mechanisms. This complexity is frequently compounded by multiple driver mutations 
within these regulatory pathways, which accumulate over time as tumours grow and develop, react 
to metabolic constraints, respond to the tumour micro-environment and adapt following chemo- 
and radio-therapy cycles. These mutations do not occur in isolation, and it is the accumulation of 
these mutations which give rise to the extensive tumour heterogeneity and diverse mechanisms of 
therapeutic evasion displayed by pHGG. Perhaps the most significant consideration is the 
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appropriate application of radio- and chemo-therapy which may drive an increasingly aggressive, 
adaptive and resistant phenotype characterized by autophagy deregulation (Figure 4). 
The search for efficacious clinical candidates for the treatment of pHGG remains critical. This 
can incorporate validating novel therapeutic candidates, repurposing clinically available molecules, 
or combinatorial chemotherapies to sensitize these tumours to radio- and chemo-therapy. Any 
potential therapy must minimise adverse toxicity and maintain efficacy over long term use. 
Therapeutic design must increasingly take into account the dynamic heterogeneity of pHGG, 
mechanisms of resistance and the complexity of delivering therapeutics to these tumours at an 
effective concentration. As discussed by Jones et al, pHGG clinical trials are complex, compounded 
by limited patient numbers, require multi-centre cooperation and extended time scales to achieve 
meaningful recruitment and statistical significance (20). Large groups with an inherent tumour 
heterogeneity may mask any positive impact of a smaller sub-group contained within it. In addition, 
a small group may never achieve significant patient numbers for downstream analysis and statistical 
scrutiny. The complexity of inclusion criteria within clinical trials must also be considered. Patients 
entering clinical trials have typically been exposed to, and failed to respond to, a variety of 
aggressive treatments. The effect of pre-exposure on tumour malignancy and therapy resistance 
should be considered within the clinical trial design. Profiling patients to determine genetic and 
epigenetic expression is likely to be the key to designing and applying clinically relevant therapeutics 
during the development of adaptive clinical trials. Here we describe the importance of autophagy 
within pHGG, where the modulation of autophagy offers scope for more efficacious, better 
tolerated, and tailored therapeutic options for young patients and warrants extensive further study. 
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Figure 1. Macro-/micro-, chaperone mediated autophagy and mitophagy. The processes 
collectively described as ‘autophagy’ are subdivided by the nature in which substrates for 
degradation are selected and delivered to the lysosome. Micro-autophagy is a cellular pathway 
which is mediated by direct lysosomal engulfment of the cytoplasmic cargo. Cytoplasmic material is 
trapped in the lysosome/vacuole by the random process of membrane invagination. Chaperone-
dependent autophagy involves the selection of soluble cytosolic proteins that are then targeted to 
lysosomes and directly translocated across the lysosome membrane for degradation. The unique 
features of this type of autophagy are the selectivity on the proteins that are degraded by this 
pathway and the direct shuttling of these proteins across the lysosomal membrane without the 
requirement for the formation of additional vesicles. Macro-autophagy (typically termed 
‘autophagy’), is the cellular network where targeted cytoplasmic components are isolated from the 
cytoplasm within a double-membraned vesicle called an autophagosome. The autophagosome fuses 
with lysosomes and the contents are degraded, recycled and released back into the cytoplasm. 
Mitophagy is the selective degradation of mitochondria by autophagy. Mitophagy promotes 
turnover of mitochondria and prevents the accumulation of dysfunctional mitochondria. Mitophagy 
is regulated by the PINK1 and parkin proteins. 
Figure 2. (Top) Major pathways involved in Autophagy Regulation. Autophagy regulation is 
complex and tightly regulated, with multiple activators and inhibitors. (Green) Growth factor binding 
at the cell surface receptors activate PTEN, a major negative regulator of autophagy (shown in red). 
PTEN dephosphorylates PIP3 to PIP2, inhibiting AKT signalling. PTEN deactivation, or reduction in 
growth factor signalling permits formation of PIP3, recruiting AKT to the plasma membrane where it 
is phosphorylated and activated. Activated Akt phosphorylates and inactivates Tuberculosis Sclerosis 
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1/2 (TSC1/2), releasing Rheb2 to activate mTORC and inhibiting autophagy. Activated AKT inhibits 
Foxo3a, ablating transcription of autophagy related genes, including various ATG’s and LC3. 
Abundant amino acids activate Rheb2, activating mTORC and preventing autophagy induction. High 
ATP/AMP ratio inhibits AMPK, inhibiting TSC1/2 activation and Rheb activation of mTORC1, 
inhibiting autophagy. In addition, AMPK phosphorylates ULK1, stimulating ULK1 complex and 
promoting autophagy. Elevated p53, as a result of DNA damage (shown in blue) (and other assaults) 
activate AMPK and inhibit downstream signalling by Rheb, inhibiting mTORC1 and abolishing 
downstream autophagy signalling. DNA damage (and elevated glucose) leads to activation of JUN N-
terminal kinase (JNK) pathway and phosphorylation of Bcl-2. Phosphorylated Bcl-2 dissociates from 
Beclin1, allowing Beclin1/VPS34 complex formation and autophagy induction. Glucose (grey), (a 
major source of ATP, shown in purple) restriction triggers AMPK activation and suppression of 
mTORC1 (by Rheb). Both elevated and depleted glucose levels may lead to accumulation of ROS 
leading to endoplasmic reticulum (ER) stress and induction of autophagy by AMPK and JNK 
networks. Glucose deprivation may also induce a p53/AMPK positive feedback loop, in which p53 is 
phosphorylation by AMPK, via the ATM kinase, leading to nuclear translocation of p53. AMPK is 
further activated by p53 transcription targets. (Bottom) Overview of autophagy. Autophagy is 
negatively regulated by protein kinase AMPK (Adenosine monophosphate activated protein kinase) 
and mTOR (mammalian target of rapamycin), via phosphorylation of ULK1 complex.  During times of 
stress, including nutrient deprivation or by the action of radio- and chemotherapy, mTORC1 
(mammalian target of rapamycin complex1) becomes functionally coupled to ULK1 (UNC-51-like 
kinase-1)-FIP200 (FAK family kinase-interacting protein of 200kDa)-ATG12-ATG101 complex, which 
phosphorylates Beclin-1. VPS34-Beclin1 complex, regulated by BCL2 (apoptosis associated) family 
proteins locate to PAS (phagophore assembly site). ATG9 and VMP1 (vacuole membrane protein) 
recruit lipids to the phagophore for elongation of the membrane. Autophagosome assembly and 
maturation involves two ubiquitin-like (UBL) conjugation systems; the light chain (LC3) and ATG12 
UBL systems. In the ATG12 UBL system, ATG12 becomes covalently bound to ATG5, catalysed by 
ATG10 and ATG7. ATG12-ATG5 complex binds to ATG16, and the resulting ATG12-ATG5-ATG16 
complex interacts with LC3 UBL system. ATG4 protease, cleaves LC3 at carboxyl terminal allowing 
ATG3 to covalently bind PE (phosphatidylethanolamine) to LC3 for membrane elongation, cargo 
recognition and fusion of lysosomes to autophagosome. Cellular organelles and macro-molecules 
are tagged with Lys63 ubiquitin and are sequestered into double membraned autophagosome 
during membrane elongation. Autophagosome fuses with lysosome, forming autophagolysosome 
and are degraded by hydrolase and lysosome enzymes. 
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Figure 3. Tumour location, patient survival and tissue microarray staining for key autophagy and 
proliferation markers. A). 20 patient biopsies were obtained from various regions within the brain. 
Radius of the circle is proportional to the number of cases. Patient #19 and #20, primary tumour 
location data was absent. B). Overall survival was plotted for this patient cohort and C). Stained for 
LC3 A/B, Beclin1, Ki67 and Haematoxylin and Eosin staining. Images shown are at 13.5x and (inset) 
35.5x magnification. All were obtained using a Hamamatsu NanoZoomer-SQ Digital slide scanner and 
quantified using an IHC profiler package within ImageJ (134). 
Figure 4. Tissue Microarray staining for key autophagy and proliferation markers in an original 
treatment naïve and relapse pHGG tumour. LC3 A/B, Beclin1, Ki67 and Haematoxylin and Eosin 
staining was conducted for each core from this patient (grade IV GBM where the original tumour 
was located within the temporal lobe) in the original and the relapse biopsy samples (following the 
indicated treatment regimen) and shown at 13.5x magnification and (inset) 35.5x. Images were 
obtained using a Hamamatsu NanoZoomer-SQ Digital slide scanner and quantified using an IHC 
profiler package within ImageJ (134). 
 
Table 1. Clinical trial summary in pHGG. Shown are the various clinical trials and their respective 
completion stage for pHGG using agents that target (directly or indirectly) autophagy. Included are 
the respective phase for each trial and the age selection criteria.  
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Trial ID Therapeutic(s) Tumour Type 
Age 
(years) 
Phase 
Primary Outcome 
Measure 
Status 
NCT01331135 Sirolimus 
Solid Refractory 
Tumours 
Up to 30 Phase I 
Maximum tolerated 
dose (MTD) 
Active, not 
yet 
recruiting 
NCT01282697 
Rapamycin and 
Iranotecan 
Solid Refractory 
Tumours 
1 - 21 Phase I 
Maximum tolerated 
dose (MTD) Dose 
limiting toxicity 
(DLT) 
inactive 
since 2013 
NCT01670175 
Sirolimus, 
combined 
cyclophosphami
de and 
topotecan 
Solid Tumour 1 - 30 Phase I 
Dose limiting 
toxicity (DLT) 
Completed. 
NCT02015728 
Temozolomide,  
Etoposide, 
Everolimus plus 
Erlotinib, 
Dasatinib or 
Sorafenib 
Brain Tumour 
1 month 
– 30 
Feasibility 
Efficacy, Survival, 
Toxicity 
Active, not 
recruiting 
NCT00187174 Evirolimus 
Recurrent/ Refractory 
Solid including Brain 
Tumours 
3 - 21 Phase I 
Maximum tolerated 
dose (MTD) 
Completed 
NCT03387020 
Everolimus and 
Ribociclib 
Malignant glioma, 
recurrent and 
refractory DIPG, 
Ependymoma, 
Medulloblastoma, ATRT 
1 – 21 Phase I 
Maximum tolerated 
dose (MTD) Overall 
response 
Recruiting 
NCT02233049 
Everolimus, 
Erlotinib, 
Dasatinib 
(Combinatorial) 
DIPG with 
EGFR overexpression, 
PTEN loss or 
combination mutations 
6 months 
– 25 
Phase II 
Overall survival (2 
years) 
Recruiting 
NCT00880282 
Temsirolimus 
and 
Cixutumumab 
Recurrent/ refractory 
solid tumours 
1 - 30 Phase I 
Maximum tolerated 
dose (MTD) 
Completed 
NCT01614795 
Temsirolimus 
and 
Cixutumumab 
Recurrent/ refractory 
solid tumours 
1 - 30 Phase II 
Objective response 
rate 
Toxicity 
Completed 
NCT03213678 
mTOR/DNA-PK 
dual inhibitor 
LY3023414 
Solid tumours 1 – 21 
Phase II 
Paediatirc 
MATCH 
Response rate (3 
years) 
Recruiting 
NCT02813135 
Combinatorial, 
including 
Everolimus 
Recurrent/ Refractory 
Tumours, excluding 
metastases 
Up to 18 
Phase I/ 
Phase II 
Objective tumour 
response Time to 
progression. 
Recruiting 
NCT01677741 
Debrafenib 
(BRAF V600 
mutant) 
Paediatric low and high 
grade gliomas with 
BRAFV600E mutation 
1 -17 Phase I 
Maximum tolerated 
dose (MTD) 
Dose limiting 
toxicity (DLT) 
Recruiting 
NCT01748149 Vemurafenib 
Recurrent/ Refractory 
gliomas 
Up to 25 Phase I 
Maximum tolerated 
dose (MTD) 
Active, not 
recruiting 
NCT02684058 
Dabrafenib  and 
Trametinib (MEK 
1/2 inhibitor) 
BRAF V600E positive 
low grade and 
recurrent/refractory 
high grade glioma 
1 – 25 Phase II 
Overall response 
rate (ORR) over 4 
months 
Recruiting 
NCT00883688 
Bevacizumab 
and labatinib 
Ependymoma Up to 21 Phase II 
Objective response 
rate 
Completed, 
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NCT03696355 
GDC-0084 PI3K 
inhibitor 
Peadiatric high grade 
glioma 
2 – 21 Phase I 
Maximum tolerated 
dose (MTD) after 
radiotherapy 
Recruiting 
NCT01158300 
PTC299 VEGF 
inhibitor 
Recurrent or refractory 
CNS tumours 
3 – 21 Phase I 
Maximum tolerated 
dose (MDT) Adverse 
events 
Completed 
NCT00077454 
Erlotonib + 
temozolomide 
Recurrent/ refractory 
solid tumours 
Up to 21 Phase I 
Maximum tolerated 
dose (MDT) Dose 
limiting toxicity 
(DLT) 
Completed 
NCT03654716 
ALRN-6924 dual 
MDM2/MDMX 
inhibitor 
Solid tumours including 
brain tumour 
1 – 21 Phase 1 
Dose limiting 
toxicity (DLT) 
Recruiting 
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